Early relapses, onset of progression, and late outcome in multiple sclerosis

Antonio Scalfari1, Anneke Neuhaus, Martin Daumer

  • 1Centre for Neuroscience, Division of Experimental Medicine, Imperial College London, London, England.

JAMA Neurology
|February 15, 2013
PubMed
Abstract

Insights

Early relapses in multiple sclerosis (MS) do not reliably predict secondary progression (SP) or long-term disability. Outcomes vary significantly, even in patients with frequent early attacks, questioning relapse frequency as a disability marker.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Clinical Neuroscience

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Understanding factors predicting disease progression is crucial for patient management.
  • Early relapses and secondary progression (SP) are key clinical milestones in MS.

Purpose of the Study:

  • To investigate the relationship between early relapses (first 2 years) and the onset of secondary progression (SP) in MS.
  • To determine if early relapse frequency predicts long-term disability in MS patients.
  • To assess the predictive value of time to SP on disability milestones.

Main Methods:

  • A 28-year longitudinal cohort study of 730 patients with relapsing-remitting MS.
  • Analysis of patients diagnosed using Poser criteria from the London Multiple Sclerosis Clinic database.
  • Assessment of the impact of early relapse frequency and latency to SP on disability progression (cane requirement, bedridden status).

Main Results:

  • Frequent early relapses (≥3 in 2 years) showed variable outcomes; 65.2% rapidly progressed to SP, while 34.8% did not, despite early inflammatory activity.
  • Longer time to SP was associated with a lower probability of reaching significant disability (cane use, bedridden status).
  • The duration of the relapsing-remitting phase did not affect the time from SP onset to severe disability.

Conclusions:

  • Early inflammatory attacks in MS may be dissociated from the onset of secondary progression.
  • Relapse frequency in the early disease course is not a reliable surrogate marker for predicting long-term disability.
  • Significant outcome variability exists among MS patients, even those with frequent early relapses.

Related Concept Videos

Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation01:25

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Introduction to Language of Pathophysiology ll01:17

Introduction to Language of Pathophysiology ll

This lesson explores key terms that describe how diseases progress, their outcomes, and their distribution in populations.Diagnostic tests identify diseases and monitor treatment. These include blood and urine tests, biopsies, imaging (X-ray, MRI), and detection of infectious agents.Remission is a reduction or disappearance of symptoms.Exacerbation refers to the worsening of symptoms, such as increased wheezing during an asthma attack.A precipitating factor triggers an acute episode, while a...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...